吉非替尼治疗晚期非小细胞肺癌临床观察

THE CLINICAL OBSERVATION OF GEFITINIB IN TREATING ADVANCED STAGE NSCLC

[目的]观察吉非替尼治疗晚期非小细胞肺癌的疗效与毒副反应。[方法]57例经病理学诊断的晚期(ⅢA期或Ⅳ期)非小细胞肺癌患者入组,口服吉非替尼250mgQd。统计方法:疗效评价用χ检验。[结果]所有257例均可评价疗效:CR4例,PR27例,SD7例,PD19例;其中,性别,吸烟史,PS评分,病理类型及既往化疗方案数都与RR相关。生存期随访至2007年1月,全组中位生存时间5.1个月(1～27个月),中位疾病进展时间3个月(0.5～25个月),36例6个月内出现进展,16例服药6～12个月进展,1年生存率25.4%。不良反应以皮疹、腹泻、恶心呕吐为主,多为轻度。[结论]吉非替尼治疗晚期NSCLC有较好的安全性和有效性;女性有效率高于男性;PS现状好者效果优于PS差者;不吸烟者效果高于吸烟者,一线治疗5例中4例有效(均为女性,腺癌3例,鳞癌1例。)

[Objective] To observe the curauve and side effect of advanced stage non-small cell lung cancer treating by gefitinib. [ Methods ]Analyzed 57 patients with advanced stage NSCLC （ Ⅲ A or Ⅳ ） who were confirmed by pathology. All of them were orally administrated with gefinitib 250mg/d. Statistical method： the anticancer effects were analyzed by ）χ^2 test. [Resuits] All the 57 patients could be evaluated. 4 cases CR; 27 cases PR; 7 cases SD and 19 cases PD. In which, sex, history of smoking, PS, pathology type and the number of chemotherapy forms were related to RR respectively. Life span was followedup to Jan.2007, The middle survival time was 5.1 months （1-27months）. The middle time of progression was 3 months （0.5-25months） , 36 patients got disease progress in 6 months and 16 patients got in 6-12 months. The 1 year survival rate was 25.4%. The most common drug related adverse events were rash, diarrhea, nausea and vomit, most of which were endurable. [Conclusion] Treating advanced stage NSCLC with gefitinib seems to be safe and effective. Female, PS 〈 1 and non-smoking are related to higher effectivity. In first line therapy, 4 eases in 5 get effective results （all female, 3 cases adenocarcinoma and 1 ease squamous carcinoma） .